PMID- 25720763
OWN - NLM
STAT- MEDLINE
DCOM- 20170327
LR  - 20181113
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Print)
IS  - 1399-543X (Linking)
VI  - 17
IP  - 4
DP  - 2016 Jun
TI  - Changes in beta cell function during the proximate post-diagnosis period in 
      persons with type 1 diabetes.
PG  - 237-43
LID - 10.1111/pedi.12271 [doi]
AB  - OBJECTIVE: Prior studies examining beta-cell preservation in type 1 diabetes have 
      predominantly assessed stimulated C-peptide concentrations approximately 10 wk 
      after diagnosis. We examined whether earlier assessments might aid in prediction 
      of beta cell function over time. METHODS: Using data from a multi-center 
      randomized trial assessing the effect of intensive diabetes management initiated 
      within 1 wk of diagnosis, we assessed which clinical factors predicted 90-min 
      mixed-meal tolerance test (MMTT) stimulated C-peptide values obtained 2 and 6 wk 
      after diagnosis. We also studied associations of these factors with C-peptide 
      values at 1- and 2-year post-diagnosis. Data from intervention and control groups 
      were pooled. RESULTS: Among 67 study participants (mean age 13.3 +/- 5.7 yr, range 
      7.8-45.7 yr) in multivariable analyses, C-peptide increased from baseline to 2 
      wks and then 6 wk. C-peptide levels at these times were significantly correlated 
      with 1- and 2-yr C-peptide concentrations (all p < 0.001), with the strongest 
      observed associations between 6-wk C-peptide and the 1- and 2-yr values (r = 0.66 
      and r = 0.61, respectively). In multivariable analyses, greater baseline and 6-wk 
      C-peptide, and older age independently predicted greater 1- and 2-yr C-peptide 
      concentrations. CONCLUSIONS: C-peptide assessments close to diagnosis were 
      predictive of subsequent C-peptide production. Our data demonstrate a clear 
      increase in C-peptide over the initial 6 wk after diabetes diagnosis followed by 
      a plateau. Our data do not suggest that MMTT assessments performed closer to 
      diagnosis than 6 wk would improve prediction of subsequent residual beta cell 
      function.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - DiMeglio, Linda A
AU  - DiMeglio LA
AD  - Department of Pediatrics, Section of Pediatric Endocrinology/Diabetology, Indiana 
      University, Riley Hospital for Children, Indianapolis, IN, USA.
FAU - Cheng, Peiyao
AU  - Cheng P
AD  - Jaeb Center for Health Research, Tampa, FL, USA.
FAU - Beck, Roy W
AU  - Beck RW
AD  - Jaeb Center for Health Research, Tampa, FL, USA.
FAU - Kollman, Craig
AU  - Kollman C
AD  - Jaeb Center for Health Research, Tampa, FL, USA.
FAU - Ruedy, Katrina J
AU  - Ruedy KJ
AD  - Jaeb Center for Health Research, Tampa, FL, USA.
FAU - Slover, Robert
AU  - Slover R
AD  - Barbara Davis Center for Childhood Diabetes, University of Colorado School of 
      Medicine, Aurora, CO, USA.
FAU - Aye, Tandy
AU  - Aye T
AD  - Pediatric Endocrinology, Stanford University, Stanford, CA, USA.
FAU - Weinzimer, Stuart A
AU  - Weinzimer SA
AD  - Pediatric Endocrinology, Yale University, New Haven, CT, USA.
FAU - Bremer, Andrew A
AU  - Bremer AA
AD  - Division of Pediatric Endocrinology, Vanderbilt University Medical Center, 
      Nashville, TN, USA.
FAU - Buckingham, Bruce
AU  - Buckingham B
AD  - Pediatric Endocrinology, Stanford University, Stanford, CA, USA.
CN  - Diabetes Research in Children Network (DirecNet); Type 1 Diabetes TrialNet Study 
      Group
LA  - eng
GR  - U01 DK085476/DK/NIDDK NIH HHS/United States
GR  - U10 HD041906/HD/NICHD NIH HHS/United States
GR  - U01 DK061010/DK/NIDDK NIH HHS/United States
GR  - U01 DK085466/DK/NIDDK NIH HHS/United States
GR  - U01 DK103153/DK/NIDDK NIH HHS/United States
GR  - U01 DK061058/DK/NIDDK NIH HHS/United States
GR  - U01 DK085505/DK/NIDDK NIH HHS/United States
GR  - U01 DK106984/DK/NIDDK NIH HHS/United States
GR  - U01 HD041890/HD/NICHD NIH HHS/United States
GR  - U10 HD041908/HD/NICHD NIH HHS/United States
GR  - U01 DK107014/DK/NIDDK NIH HHS/United States
GR  - U01 DK061042/DK/NIDDK NIH HHS/United States
GR  - U10 HD041890/HD/NICHD NIH HHS/United States
GR  - U01 DK085509/DK/NIDDK NIH HHS/United States
GR  - U01 DK085465/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150227
PL  - Denmark
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
RN  - 0 (C-Peptide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - C-Peptide/*blood
MH  - Child
MH  - Diabetes Mellitus, Type 1/*blood/physiopathology
MH  - Humans
MH  - Insulin-Secreting Cells/*physiology
MH  - Middle Aged
MH  - Young Adult
PMC - PMC4551616
MID - NIHMS668677
OTO - NOTNLM
OT  - clinical science
OT  - diabetes in childhood
OT  - insulin secretions in vivo
COIS- R. Beck, K. Ruedy, P. Cheng, T. Aye, and L. DiMeglio have no relevant conflicts 
      of interest to disclose.
EDAT- 2015/02/28 06:00
MHDA- 2017/03/28 06:00
PMCR- 2017/06/01
CRDT- 2015/02/28 06:00
PHST- 2014/11/03 00:00 [received]
PHST- 2015/02/02 00:00 [revised]
PHST- 2015/02/05 00:00 [accepted]
PHST- 2015/02/28 06:00 [entrez]
PHST- 2015/02/28 06:00 [pubmed]
PHST- 2017/03/28 06:00 [medline]
PHST- 2017/06/01 00:00 [pmc-release]
AID - 10.1111/pedi.12271 [doi]
PST - ppublish
SO  - Pediatr Diabetes. 2016 Jun;17(4):237-43. doi: 10.1111/pedi.12271. Epub 2015 Feb 
      27.